JPRN-jRCT2080223177已完成3 期
Phase III Study of S-877503 in Adult Patients with Attention-deficit/Hyperactivity Disorder -long term extension study
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 191
研究概览
简要总结
ong-term administration of S-877503 poses no serious safety concern and suggested that the efficacy was sustained in ADHD patients aged 18 years or more.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patient has completed 12-week administration in the preceding study of S-877503 in adult with ADHD, etc.
排除标准
- •Patient has complications such as serious hepatic disorder, renal disorder, heart disease, lung disease, hematological disease, and metabolic disease.
- •Patient has suicidal tendency. etc.
研究者
相似试验
已完成
1 期
Single dose study of SK-0348Healthy adult subjectsJPRN-jRCT2071220001Kenji Asano46
进行中（未招募）
不适用
An open-label safety study of S-888711 in adult subjects with relapsed persistent or chronic immune thrombocytopenia with or without prior splenectomy - NDEUCTR2009-017942-30-ITSHIONOGI USA, INC60
进行中（未招募）
不适用
An open-label safety study of S-888711 in adult subjects with relapsed persistent or chronic immune thrombocytopenia with or without prior splenectomyRelapsed persistent or chronic immune thrombocytopenia with or without prior splenectomyMedDRA version: 12.1Level: LLTClassification code 10066667Term: Chronic thrombocytopeniaMedDRA version: 12.1Level: LLTClassification code 10063129Term: Persisting thrombocytopeniaEUCTR2009-017942-30-DEShionogi USA, Inc.60
进行中（未招募）
不适用
An open-label safety study of S-888711 in adult subjects with relapsed persistent or chronic immune thrombocytopenia with or without prior splenectomyEUCTR2009-017942-30-GBShionogi USA, Inc.60
进行中（未招募）
不适用
An open-label safety study of S-888711 in adult subjects with relapsed persistent or chronic immune thrombocytopenia with or without prior splenectomyEUCTR2009-017942-30-FRShionogi USA, Inc.60